Joincare Pharmaceutical Group Industry Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
Joincare Pharmaceutical Group Industry Co.,Ltd. carries a market capitalization of 18.75B, placing it among publicly traded companies globally. Its enterprise value stands at 19.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 18.75B |
| Enterprise Value | 19.79B |
Share Statistics
Joincare Pharmaceutical Group Industry Co.,Ltd. currently has 1.83B shares outstanding.
| Shares Outstanding | 1.83B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Joincare Pharmaceutical Group Industry Co.,Ltd. trades at a trailing price-to-earnings ratio of 14.98. The price-to-sales ratio is 1.37, and the price-to-book ratio stands at 1.64.
| PE Ratio | 14.98 |
| PS Ratio | 1.37 |
| PB Ratio | 1.64 |
| P/TBV Ratio | 0.96 |
| P/FCF Ratio | 22.40 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Joincare Pharmaceutical Group Industry Co.,Ltd. trades at an EV/EBITDA multiple of 5.76 and an EV/FCF ratio of 19.53. The EV/Sales ratio of 1.29 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 5.76 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.29 |
| EV / EBITDA | 5.76 |
| EV / EBIT | 5.76 |
| EV / FCF | 19.53 |
Financial Position
Joincare Pharmaceutical Group Industry Co.,Ltd. maintains a current ratio of 2.57, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.14, indicating elevated leverage, while an interest coverage ratio of 35.62 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.57 |
| Quick Ratio | 1.65 |
| Debt / Equity | 21.14 |
| Debt / EBITDA | 1.45 |
| Interest Coverage | 35.62 |
Financial Efficiency
Joincare Pharmaceutical Group Industry Co.,Ltd. posts a return on equity of 11.39 and a return on invested capital of 10.04.
| Return on Equity (ROE) | 11.39 |
| Return on Assets (ROA) | 3.87 |
| Return on Invested Capital (ROIC) | 10.04 |
| Return on Capital Employed (ROCE) | -0.69 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.36 |
Taxes
Over the trailing twelve months, Joincare Pharmaceutical Group Industry Co.,Ltd. has paid 615.35M in income taxes, reflecting an effective tax rate of 16.79.
| Income Tax | 615.35M |
| Effective Tax Rate | 16.79 |
Stock Price Statistics
Joincare Pharmaceutical Group Industry Co.,Ltd.'s stock has declined approximately -10.4021% over the past 52 weeks. The 50-day moving average sits at 10.23, while the 200-day moving average is 11.39.
| Beta (5Y) | N/A |
| 52-Week Price Change | -10.4021% |
| 50-Day Moving Average | 10.23 |
| 200-Day Moving Average | 11.39 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Joincare Pharmaceutical Group Industry Co.,Ltd. generated 15.28B in revenue and converted that into 1.40B in net income, yielding earnings per share of 1.61. EBITDA reached 3.44B, while operating income came in at 3.44B.
| Revenue | 15.28B |
| Gross Profit | 9.49B |
| Operating Income | 3.44B |
| Pretax Income | 3.67B |
| Net Income | 1.40B |
| EBITDA | 3.44B |
| EBIT | 3.44B |
| Earnings Per Share (EPS) | 1.61 |
Balance Sheet
Joincare Pharmaceutical Group Industry Co.,Ltd. holds 14.98B in cash and equivalents against 4.98B in total debt, resulting in a net debt position of -10.07B. Total book value stands at 12.74B, with working capital of 14.29B providing operational flexibility.
| Cash & Cash Equivalents | 14.98B |
| Total Debt | 4.98B |
| Net Debt | -10.07B |
| Equity (Book Value) | 12.74B |
| Book Value Per Share | 6.72 |
| Working Capital | 14.29B |
Cash Flow
After subtracting -932.97M in capital expenditures, free cash flow totaled -932.97M - equivalent to -0.49 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -932.97M |
| Free Cash Flow | -932.97M |
| FCF Per Share | -0.49 |
Margins
Joincare Pharmaceutical Group Industry Co.,Ltd. operates with a gross margin of 62.10, reflecting its pricing power and cost economics. The operating margin of 22.50 and net profit margin of 9.13 provide insight into operational efficiency.
| Gross Margin | 62.10 |
| Operating Margin | 22.50 |
| Pretax Margin | 23.98 |
| Profit Margin | 9.13 |
| EBITDA Margin | 22.50 |
Dividends & Yields
The company's payout ratio of 9.63 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.24 |
| Dividend Yield | N/A |
| Payout Ratio | 9.63 |
| Shareholder Yield | 15.64 |
| FCF Yield | 4.46 |
Stock Splits
Joincare Pharmaceutical Group Industry Co.,Ltd.'s most recent stock split took place on October 16, 2018 with a 200:221 split ratio.
| Last Split Date | 10/16/2018 |
| Split Ratio | 200:221 |
Scores
Joincare Pharmaceutical Group Industry Co.,Ltd. posts an Altman Z-Score of 2.79, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.79 |